German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario, Canada.

The five-year partnership will provide Canadian academic institutions and teaching hospitals with access to Evotec’s infrastructure and drug-discovery expertise that will be combined with the latest drug discovery projects initiated by the 15 MI member institutions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The LAB150 partnership addresses challenges related to the lack of funding, specialised infrastructure and drug development expertise that is essential for the translation of disease-related biological pathways into effective drug-discovery programmes.

The joint effort between Evotec and MI is centered on significantly reducing the drug discovery timeline and establishing suitable start-up companies.

"LAB150 represents an extraordinary opportunity for Canada to bridge the drug discovery gap."

As part of the collaboration, MI will identify projects and develop technical and business cases from scientific concepts that focus on new and disease-related novel biological pathways.

Evotec will be responsible for contributing infrastructure and pre-clinical drug-development expertise to transform the discoveries into potential treatments.

MI president and chief executive officer Dr Rafi Hofstein said: “LAB150 represents an extraordinary opportunity for Canada to bridge the drug discovery gap with the objective of stimulating the formation of new ventures in downtown Toronto and of developing groundbreaking therapies to benefit Canadians and others around the world.”

The partnership will help boost the development and commercialisation of new Canadian therapies across the globe.